ArticleJournal of clinical medicine2024
Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months.
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Pooled it
- Comparative effects of six exercise modalities on global cognitive function in Alzheimer's disease, Parkinson's disease, and mild cognitive impairment: a systematic review and network meta-analysis.Frontiers in neurology · 2026Pooled it
- Technology-Assisted Cognitive Support for Older Adults With Mild Cognitive Impairment: Study Protocol for the DHEAL-COM COGNITIVE Quasi-Experimental Pilot Study.JMIR research protocols · 2026Article
- Neurophysiological Differentiation of Conversion to Alzheimer's Disease: Longitudinal Changes in P300 Amplitude as an Indicator of Mild Cognitive Impairment Progression.Brain and behavior · 2026Article
- The role of NLRP3 neuroinflammation in cognitive frailty diversity during aging and after LPS administration in mice.Scientific reports · 2026Article
- Liver Fibrosis and the Risks of Impaired Cognition and Dementia: Mechanisms, Evidence, and Clinical Implications.Medical sciences (Basel, Switzerland) · 2026Review
- Risk Factors and Annual Rates of Cognitive Decline in Elderly Mild Cognitive Impairment: A Retrospective Cohort Study.Neuropsychiatric disease and treatment · 2026Article
- Prediction of cognitive impairment through speech data analysis: A comparative evaluation of deep learning models.PloS one · 2026Article
- Cognitive Status Classification Among Older Adults: A Study from SHARE-HCAP.Journal of clinical medicine · 2025Article
- Functionalized Magnetic Nanoparticles: Can They Revolutionize the Treatment of Neurodegenerative Disorders?Materials (Basel, Switzerland) · 2025Review
- Development and Validation of a Brain Aging Biomarker in Middle-Aged and Older Adults: Deep Learning Approach.JMIR aging · 2025Article
- Longitudinal Analysis of Amyloid PET and Brain MRI for Predicting Conversion from Mild Cognitive Impairment to Alzheimer's Disease: Findings from the ADNI Cohort.Tomography (Ann Arbor, Mich.) · 2025Article
- Cognitive health promotion through a low-intensity high-volume webinar intervention for older adults at risk of future dementia.Frontiers in psychology · 2025Article
- Investigating the factor structure of the Montreal Cognitive Assessment: a qualitative review.Frontiers in psychology · 2025Review
- Yoga an integrated mind body intervention for improvement in quality of life in individuals with Alzheimer's disease and their caregivers.Frontiers in aging · 2025Article
- The Effect of Levels of Leisure-Time Physical Activity on Cognitive Functions Among Older Adults with Mild Cognitive Impairment: A Longitudinal Analysis.Gerontology & geriatric medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to elucidate the long-term progression of mild cognitive impairment (MCI) within a comprehensive longitudinal dataset, distinguish it from healthy aging, explore the influence of a dementia subtype on this progression, and identify potential contributing factors. Patients with prodromal and preclinical cases underwent regular neuropsychological assessments utilizing various tools. The study included a total of 140 participants with MCI, categorized into Alzheimer's disease (AD) and non-AD subtypes. Our dataset revealed an overall progression rate of 92.8% from MCI to the clinical stage of dementia during the follow-up period, with an annual rate of 15.7%. Notably, all prodromal cases of Lewy body dementia/Parkinson's disease (LBD/PDD) and frontotemporal dementia (FTD) advanced to clinical stages, whereas 7% of vascular dementia (VaD) cases and 8.4% of AD cases remained in the prodromal stage throughout follow-up. Furthermore, we observed a faster progression rate in MCI-AD cases compared to non-AD sufferers (53.9% vs. 35.5%, Entropy: 0.850). This study revealed significant cognitive changes in individuals with MCI over time. The mini-mental state examination (MMSE), global deterioration scale (GDS), and calculation tests were the most effective tests for evaluation of MCI. These findings may offer valuable insights for the development of personalized interventions and management strategies for individuals with MCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.